<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01912534</url>
  </required_header>
  <id_info>
    <org_study_id>VANISH</org_study_id>
    <secondary_id>5P50HL112349</secondary_id>
    <nct_id>NCT01912534</nct_id>
  </id_info>
  <brief_title>Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM</brief_title>
  <acronym>VANISH</acronym>
  <official_title>Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HealthCore-NERI</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>HealthCore-NERI</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine whether treatment with valsartan will have&#xD;
      beneficial effect in early hypertrophic cardiomyopathy (HCM) by assessing many domains that&#xD;
      reflect myocardial structure, function and biochemistry.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, double-blind, placebo-controlled Phase II, randomized clinical trial&#xD;
      to assess the safety and efficacy of valsartan in attenuating disease evolution in early HCM.&#xD;
      Sarcomere mutation carriers with asymptomatic or mildly symptomatic overt disease (NYHA class&#xD;
      I-II), and mutation carriers without left ventricular hypertrophy (LVH) will be studied.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Actual">July 2019</completion_date>
  <primary_completion_date type="Actual">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite z-score</measure>
    <time_frame>2 years</time_frame>
    <description>Composite z-score which is the average of 9 change-scores of: serum NTproBNP, serum high-sensitivity cardiac troponin, left ventricular (LV) mass, left atrial (LA) volume, LV end diastolic volume, LV end systolic volume, maximal LV wall thickness, echo E' velocity, echo S' velocity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>z-score serum NTproBNP</measure>
    <time_frame>2 years</time_frame>
    <description>Z-score for the 2 year change for serum NTproBNP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>z-score high sensitivity cardiac troponin</measure>
    <time_frame>2 years</time_frame>
    <description>Z-score for the 2 year change for high-sensitivity cardiac troponin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>z-score LV mass</measure>
    <time_frame>2 years</time_frame>
    <description>Z-score for the 2 year change in LV Mass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>z-score LA volume</measure>
    <time_frame>2 years</time_frame>
    <description>Z-score for the 2 year change in LA Volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>z-score LV end diastolic volume</measure>
    <time_frame>2 years</time_frame>
    <description>Z-score for the 2 year change in LV end diastolic volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>z-score LV end systolic volume</measure>
    <time_frame>2 years</time_frame>
    <description>Z-score for the 2 year change in LV end systolic volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>z-score maximal LV wall thickness</measure>
    <time_frame>2 years</time_frame>
    <description>Z-score for the 2 year change in Maximal LV wall thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>z-score echo E' velocity</measure>
    <time_frame>2 years</time_frame>
    <description>Z-score for the 2 year change in echo E' velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>z-score echo S' velocity</measure>
    <time_frame>2 years</time_frame>
    <description>Z-score for the 2 year change in echo S' velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary indicator of success or failure</measure>
    <time_frame>2 years</time_frame>
    <description>Success defined as an improvement at 2 years in any of the following: serum NTproBNP, serum high-sensitivity troponin, LV Mass, LA Volume, LV end diastolic volume, LV end systolic volume, Maximal LV wall thickness, echo E' velocity, or echo S' velocity</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety of valsartan as assessed by incidence of adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>Safety of valsartan as assessed by incidence of adverse events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">211</enrollment>
  <condition>Hypertrophic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who tolerate active run-in and titration to target dose of valsartan will then undergo stratified randomization and begin blinded treatment with valsartan or matched placebo on maximal tolerated dose, according to their assigned treatment group. Treatment will continue for 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects who tolerate active run-in and titration to target dose of valsartan will then undergo stratified randomization and begin blinded treatment with valsartan or matched placebo on maximal tolerated dose, according to their assigned treatment group. Treatment will continue for 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>40, 80 and 160 mg tablets of Valsartan</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Valsartan</arm_group_label>
    <other_name>Diovan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>During Active Run-In, all patients take Valsartan. During maintenance, all patients are randomized to valsartan or placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Valsartan</arm_group_label>
    <other_name>Matching Placebo pills</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. All subjects must have a Pathogenic or Likely Pathogenic HCM Sarcomere Mutation&#xD;
&#xD;
        a. The following categories of mutations are considered acceptable for subjects who have&#xD;
        previously undergone clinical genetic testing. If results are ambiguous, they will be&#xD;
        reviewed by the Clinical Coordinating Center to determine eligibility.&#xD;
&#xD;
          -  Laboratory for Molecular Medicine (Pathogenic, Likely Pathogenic)&#xD;
&#xD;
          -  Transgenomics/ PGXHealth (Class I)&#xD;
&#xD;
          -  GeneDx (Disease causing; Variant; likely disease-causing; Published, disease-causing&#xD;
             mutation; Novel, likely disease-causing, mutation)&#xD;
&#xD;
          -  Correlagen (Associated; Probably Associated)&#xD;
&#xD;
        Group 1 (Overt HCM Cohort)&#xD;
&#xD;
          1. LV wall thickness ≥12 mm and ≤25 mm or z score ≥3 and ≤18 as determined by rapid&#xD;
             assessment by the echocardiographic core laboratory&#xD;
&#xD;
          2. NYHA functional class I or II; no perceived or only slight limitations in physical&#xD;
             activities&#xD;
&#xD;
          3. No resting or provokable LV obstruction (peak gradient ≤ 30 mmHg) on&#xD;
             clinically-obtained Exercise Tolerance Test (ETT)-echo within the past 24 months or&#xD;
             transthoracic echo with Valsalva maneuver within the past 12 months&#xD;
&#xD;
          4. Age 8-45 years&#xD;
&#xD;
          5. Able to attend follow-up appointments, complete all study assessments, and provide&#xD;
             written informed consent&#xD;
&#xD;
        Group 2 (Preclinical HCM Cohort (G+/LVH-))&#xD;
&#xD;
          1. LV Wall Thickness &lt;12 mm and z score &lt;3 , as determined by rapid assessment by the&#xD;
             echocardiographic core laboratory&#xD;
&#xD;
          2. Age 10-25 years&#xD;
&#xD;
          3. E' z score ≤ -1.5 OR ECG abnormalities other than NSSTW changes (Q waves, T wave&#xD;
             inversion, repolarization changes) OR LV wall thickness z-score 1.5-2.9 combined with&#xD;
             LV thickness to dimension ratio ≥0.19 (as determined by rapid assessment by the&#xD;
             echocardiographic core laboratory)&#xD;
&#xD;
          4. Able to attend follow-up appointments, complete all study assessments, and provide&#xD;
             written informed consent&#xD;
&#xD;
        Subject Exclusion Criteria&#xD;
&#xD;
          1. Contraindication to angiotensin receptor blocker (ARB) administration, including&#xD;
             impaired renal function, hyperkalemia (serum K&gt;5.0 mmol/L), prior history of&#xD;
             angioedema&#xD;
&#xD;
          2. Medical conditions associated with increased collagen turnover that may confound&#xD;
             interpretation of biomarkers of collagen synthesis (liver, pulmonary or renal&#xD;
             fibrosis, inflammatory states, cancer, trauma or surgery within 6 months of&#xD;
             enrollment)&#xD;
&#xD;
          3. Concomitant use of Spironolactone, Lithium, or Aliskiren, ARB or ACE-inhibitors. If&#xD;
             these drugs are in active use but not necessary for medical care, they may be&#xD;
             discontinued and baseline studies can be performed after a 2-week washout period.&#xD;
&#xD;
          4. Pregnant or breastfeeding females - Females of childbearing potential with no&#xD;
             effective contraceptive method (including abstinence)&#xD;
&#xD;
          5. Uncontrolled systemic HTN [persistent SBP&gt;160 and/or DBP&gt;90 in adult or equivalent in&#xD;
             children (e.g., SBP&gt;99th or DBP&gt;95th percentile for sex, age, and height centile based&#xD;
             on the American Academy of Pediatrics normal values)]&#xD;
&#xD;
          6. Obstructive physiology, defined by resting, Valsalva-provoked or exercise-induced&#xD;
             gradient &gt;30mmHg within the past 24 months&#xD;
&#xD;
          7. Prior septal myectomy or alcohol septal ablation&#xD;
&#xD;
          8. Known, suspected, or symptomatic coronary artery disease or evidence of prior&#xD;
             myocardial infarction based on symptoms or cardiac imaging&#xD;
&#xD;
          9. More than mild valvular heart disease or clinically significant congenital heart&#xD;
             disease. Allowable conditions include bicuspid aortic valve without clinically&#xD;
             significant stenosis or regurgitation; spontaneously closed ventricular septal&#xD;
             defects; patent foramen ovale, small (≤ 2 mm) restrictive ventricular septal defects&#xD;
             with normal ventricular size, and other minor defects that are considered allowable&#xD;
             after [review and consensus by participating pediatric cardiologists, overall study PI&#xD;
             and] adjudication by the echocardiographic core laboratory.&#xD;
&#xD;
         10. Left ventricular ejection fraction (LVEF) &lt;55%&#xD;
&#xD;
         11. Concomitant medical conditions that would preclude performance of or confound&#xD;
             interpretation of echocardiography, exercise testing, or CMR (e.g., renal&#xD;
             insufficiency, lung disease, orthopedic/rheumatologic conditions, atrial fibrillation)&#xD;
&#xD;
         12. Secondary prevention implantable cardioverter-defibrillator device (ICD; primary&#xD;
             prevention ICDs without a history of appropriate therapy, including shock or ATP, are&#xD;
             allowable).&#xD;
&#xD;
         13. Prior treatment or hospitalization for symptomatic heart failure&#xD;
&#xD;
         14. Participation in a clinical trial (except observational studies) involving&#xD;
             investigational medications within the previous 30 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolyn Y. Ho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cinncinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4W3S5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Sick Kids</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 5, 2013</study_first_submitted>
  <study_first_submitted_qc>July 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2013</study_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sarcomere Mutations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

